Why Savara Inc.’s (SVRA) Stock Is Up 6.02%
As of Tuesday, October 20, Savara Inc.’s SVRA share price has surged by 6.02%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Commentary & Analysis
Why Savara Inc.’s (SVRA) Stock Is Up 6.24%
As of Wednesday, October 07, Savara Inc.’s SVRA share price has surged by 6.24%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Savara Inc.’s (SVRA) Stock Is Up 5.75%
As of Thursday, September 17, Savara Inc.’s SVRA share price has surged by 5.75%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Savara Inc.’s (SVRA) Stock Is Down 5.59%
As of Thursday, August 13, Savara Inc.’s SVRA share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Savara Inc.’s (SVRA) Stock Is Up 7.83%
As of Tuesday, July 21, Savara Inc.’s SVRA share price has surged by 7.83%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | SVRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,214.8 | $228.4 | 48% |
|
| Shares Out (Mil) | 253.6 | 53.9 | 80% |
|
| Institutional Ownership | 96.6% | 92.9% | 70% |
|
| Float (Mil) | 129.7 | 41.7 | 66% |
|
| Beta | 0.25 | 0.95 | 15% |
|
| Avg Daily Volume (000s) | 2,398 | 582 | 84% |
|
| Price Change (52-week) |
32.4% | 47.6% | 76% |
|
| Growth | SVRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (19.1%) | (10.1%) | 21% |
|
| EPS (5yr) | 8.2% | 15.8% | 44 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 16.9% | (15.7%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.169) | ($0.649) | ($0.367) | |
| Month Ago EPS | ($0.156) | ($0.616) | ($0.312) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.148) | ($0.580) | ($0.294) | |
| Year/Year Chg | 6.3% | 21.5% | (119.9%) | |
| Financials | SVRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($139) | ($44) | 9% |
|
| EPS (TTM) | ($0.578) | ($1.500) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($110) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $24 | $2 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $30 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | $1,220 | $177 | 43% |
|
| Valuation | SVRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.39 | 2.19 | 89% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SVRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (78.3%) | (47.1%) | 7% |
|
| ROE | (105.5%) | (54.1%) | 9% |
|
| Liabilities to Assets | 25.2% | 29.1% | 17% |
|
| F-Score | 2 | 2 | 7% |
|
Savara Inc. did not pass any screens on 10/20/2026.
